Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen.

Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of Canaccord Genuity), and Royal Bank of Canada. During the course of his career he has analyzed developments at more than 100 companies and produced over 2,000 research reports, and has developed an extensive network of investors, analysts and investment bankers. Ken also has experience working with multiple biopharmaceutical companies at the start-up to commercial stage in a variety of disease indications. He has an MBA from Thunderbird School of International Management, earned a CFA designation, and has held multiple FINRA licenses.

“Humanigen is pleased to welcome Ken,” said Cameron Durrant, CEO of Humanigen. “His background and extensive skills on Wall Street and in the biopharmaceutical space will be instrumental to Humanigen as we progress our pipeline plans.”

“Ken’s work as a covering analyst for two decades and more recently as an entrepreneur brings a unique and valuable skill set,” commented Timothy E. Morris COO/CFO of Humanigen. “We are fortunate to add Ken at this critical time in the company’s growth and look forward to leveraging his network and experience with current and future shareholders.”

Mr. Trbovich will be responsible for interfacing with investors and analysts as a key member of the Humanigen management team as the company prepares for potential distribution of lenzilumab for COVID-19 under Emergency Use Authorization, and as Humanigen expands its pipeline programs.

“I am excited to join Humanigen and utilize my market expertise to help the company continue to advance in the biopharmaceutical field,” says Ken Trbovich. “With Humanigen’s recent submission for Emergency Use Authorization for lenzilumab, the team is working to take Humanigen to the next level for commercialization and I am looking forward to assisting the company at this exciting stage.”

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of inflammation and immuno-oncology. Humanigen’s immediate focus is to prevent or minimize cytokine release syndrome that precedes severe lung dysfunction in hospitalized and hypoxic patients with COVID-19 pneumonia. Humanigen is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and cytokine release syndrome associated with CAR-T, bispecific, and other T-cell-engaging therapies, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the potential commercialization and distribution of lenzilumab if emergency use authorization were granted, and other statements regarding Humanigen’s beliefs relating to the technologies in Humanigen’s current pipeline.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the company’s lack of profitability and potential need for additional capital to grow its business; its dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. The company undertakes no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005168/en/